Ken LondonerMain MenuKen Londoner with a Device for Complex ArrhythmiaFaster and More Convenient Diagnosis in PatientsKen : Higher Prices of Medical DevicesKen Londoner Invests in Catheter AblationNew Tech Can Help Treat Atrial FibrillationKen Londoner67400b6d41c00fbf11f194dad77d72364b87b2e2Kenneth Londoner
Ken Londoner: New Tech Can Help Treat Atrial Fibrillation
12016-08-18T06:50:05-07:00Ken Londoner67400b6d41c00fbf11f194dad77d72364b87b2e2Media FilesKen Londoner3Tag: Media Filesvistag2017-02-17T05:41:53-08:00Ken Londoner67400b6d41c00fbf11f194dad77d72364b87b2e2
This page is referenced by:
12017-02-17T05:41:07-08:00New Tech Can Help Treat Atrial Fibrillation1plain2017-02-17T05:41:08-08:00For many years scientists have been looking to come up with less invasive procedures to treat Atrial Fibrillation and get better outcomes. Finally it seems that all that hard work has paid off, as we’re on the edge of discovering something big. Not long ago, when medications for irregular heart rate of atrial fibrillation failed to heal, surgery was the only treatment left. But thanks to the latest cutting edge research in this field assisted by people like Ken Londoner, doctors are finally given more options which don't involve cutting or stitching, and more importantly have quicker recovery process than surgery.
New emerging areas of research and innovation around mapping systems can allow cardiologists to see the source of atrial fibrillation, and target the areas of the heart muscle that are causing the problems. If this new technology can help reveal the source, than doctors will only have to focus on the misfiring areas, and hence increase the success rates dramatically. Starting from 2009, Ken Londoner has been leading BioSig Technologies, a medical device company that is developing technology platforms designed to improve and assist electrophysiologists. According to analysts’ forecasts, the global market for EP devices will grow from $2.5 billion in 2012 to $5.5 billion by 2019, and thus it will become one of the fastest growing medical device segments.
In order to achieve advances in catheter ablation, medical device companies like the one founded by Londoner, are putting their trust and money in 3-D imaging which can hopefully help target the right areas for treatment. Although this technology has been around for a long time, experts say that now they will take 3-D technology to the next level and will not only see anatomy in 3-D, but they'll also be able to see the propagation of the electrical waves in 3-D. As executive chairman and director of BioSig, Ken Londoner has invested a lot in this emerging technology and is planning to move forward, hoping that complications can be reduced to less than 1 percent, which is a major improvement.